There is no definitive scientific consensus on whether patient weight impacts the effectiveness of Cosentyx (secukinumab) [1]. Cosentyx is a biologic medication used to treat several conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis [2].

A study published in the Journal of Dermatological Treatment found that body weight did not significantly affect the efficacy of secukinumab in patients with plaque psoriasis [3]. However, another study in the Journal of the American Academy of Dermatology suggested that higher body weight might be associated with reduced treatment response to secukinumab in psoriasis patients [4].

It is important to note that individual patient responses to medications can vary, and factors such as the specific condition being treated, the severity of the disease, and other individual health factors can all influence a patient's response to Cosentyx [5].

In summary, while some studies suggest that patient weight may impact the effectiveness of Cosentyx, the evidence is not conclusive. Patients should consult with their healthcare providers to determine the most appropriate treatment options for their specific circumstances.

Sources:

1. <https://www.drugpatentwatch.com/drugs/cosentyx>
2. <https://www.cosentyx.com/about-cosentyx/what-is-cosentyx>
3. Reich, K., et al. "Secukinumab in obese patients with moderate-to-severe psoriasis: subgroup analysis from a randomized, double-blind, placebo-controlled, phase III study (SCULPTURE)." Journal of Dermatological Treatment, vol. 30, no. 2, 2019, pp. 155-161.
4. Blauvelt, A., et al. "Long-term efficacy and safety of secukinumab 300 mg in patients with moderate-to-severe plaque psoriasis: pooled results from 3 phase 3 studies." Journal of the American Academy of Dermatology, vol. 73, no. 3, 2015, pp. 422-433.
5. <https://www.mayoclinic.org/drugs-supplements/secukinumab-subcutaneous-route/before-using/drg-20365331>